Bindiya Vakil, CEO & co-founder of Resilinc,outlines the top five potential supply chain disruptions pharma companies should ‘watch out’ for in 2023.
Key insights:
- The nature of the pharma industry means it has to constantly react and adapt to changing market conditions, navigating uncertainties with consequences for patients if continuity of supply is interrupted.
- The ‘zero trust’ cybersecurity model became more commonplace in 2022, and will continue to be adopted by smart pharmaceuticals in 2023.
- Pharma companies should consider alternative sites to that could face production shortages and geopolitical risks, and get a plan B in place with other supply options.
The past twelve months have certainly provided another unsettled year for supply chains and international business operations, with geopolitical disruption, labour strikes, supply shortages and continued pandemic disruption.